{"id":34427,"date":"2025-05-29T16:55:33","date_gmt":"2025-05-29T08:55:33","guid":{"rendered":"https:\/\/flcube.com\/?p=34427"},"modified":"2025-05-29T16:55:33","modified_gmt":"2025-05-29T08:55:33","slug":"innocare-pharma-gains-nmpa-clinical-approval-for-bcl2-inhibitor-icp-248","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34427","title":{"rendered":"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248"},"content":{"rendered":"\n

Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969<\/a>, SHA: 688428<\/a>) announced that it has received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval paves the way for the company to evaluate its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with azacitidine for the treatment of myeloid malignancies, including myelodysplastic syndromes (MDS).<\/p>\n\n\n\n

ICP-248: A Novel BCL2 Inhibitor<\/strong>
ICP-248 represents a novel, oral, and highly selective BCL2 inhibitor. BCL2 is a pivotal regulatory protein in the apoptosis pathway, and its abnormal expression is implicated in the development of various hematological malignancies. ICP-248 selectively inhibits BCL2, restoring programmed cell death in tumor cells and thereby exerting its anti-tumor effects.<\/p>\n\n\n\n

Clinical Progress and Regulatory Milestones<\/strong>
InnoCare Pharma’s ICP-248 has been granted Breakthrough Therapy Designation (BTD) by the CDE for the treatment of patients with relapsed\/refractory mantle cell lymphoma (R\/R MCL) who are resistant to BTK inhibitors. This makes it the first BCL2 inhibitor in China to receive BTD status. Additionally, the company is accelerating patient enrollment for a regulatory Phase III study of mesutoclax in combination with orelabrutinib as first-line treatment for chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and clinical trials for acute myeloid leukemia (AML).-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical…<\/p>\n","protected":false},"author":1,"featured_media":34428,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,62,919,327,920],"class_list":["post-34427","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-clinical-trial-approval-initiation","tag-hkg-9969","tag-innocare-pharma","tag-sha-688428"],"yoast_head":"\nInnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval paves the way for the company to evaluate its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with azacitidine for the treatment of myeloid malignancies, including myelodysplastic syndromes (MDS).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34427\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248\" \/>\n<meta property=\"og:description\" content=\"Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval paves the way for the company to evaluate its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with azacitidine for the treatment of myeloid malignancies, including myelodysplastic syndromes (MDS).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34427\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-29T08:55:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2908.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248\",\"datePublished\":\"2025-05-29T08:55:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427\"},\"wordCount\":219,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2908.webp\",\"keywords\":[\"Cancer\",\"Clinical trial approval \\\/ initiation\",\"HKG: 9969\",\"InnoCare Pharma\",\"SHA: 688428\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34427#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34427\",\"name\":\"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2908.webp\",\"datePublished\":\"2025-05-29T08:55:33+00:00\",\"description\":\"Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval paves the way for the company to evaluate its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with azacitidine for the treatment of myeloid malignancies, including myelodysplastic syndromes (MDS).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34427\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2908.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2908.webp\",\"width\":1080,\"height\":608,\"caption\":\"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34427#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248 - Insight, China's Pharmaceutical Industry","description":"Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval paves the way for the company to evaluate its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with azacitidine for the treatment of myeloid malignancies, including myelodysplastic syndromes (MDS).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34427","og_locale":"en_US","og_type":"article","og_title":"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248","og_description":"Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval paves the way for the company to evaluate its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with azacitidine for the treatment of myeloid malignancies, including myelodysplastic syndromes (MDS).","og_url":"https:\/\/flcube.com\/?p=34427","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-29T08:55:33+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2908.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34427#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34427"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248","datePublished":"2025-05-29T08:55:33+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34427"},"wordCount":219,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34427#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2908.webp","keywords":["Cancer","Clinical trial approval \/ initiation","HKG: 9969","InnoCare Pharma","SHA: 688428"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34427#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34427","url":"https:\/\/flcube.com\/?p=34427","name":"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34427#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34427#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2908.webp","datePublished":"2025-05-29T08:55:33+00:00","description":"Beijing-headquartered biotech company InnoCare Pharma (HKG: 9969, SHA: 688428) announced that it has received clinical approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This approval paves the way for the company to evaluate its pipeline B-cell lymphoma-2 (BCL2) inhibitor, ICP-248, in combination with azacitidine for the treatment of myeloid malignancies, including myelodysplastic syndromes (MDS).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34427#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34427"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34427#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2908.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2908.webp","width":1080,"height":608,"caption":"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34427#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"InnoCare Pharma Gains NMPA Clinical Approval for BCL2 Inhibitor ICP-248"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2908.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34427"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34427\/revisions"}],"predecessor-version":[{"id":34429,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34427\/revisions\/34429"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34428"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}